Indexat a

Llicència i ús

Citacions

Cited 2 times in

Altmetrics

Grant support

This project has received funding from the European Union's Horizon Europe Research and Innovation Program under grant agreement No. 101104589.

Anàlisi d'autories institucional

Compartir

Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients

Publicat a:Future Oncology. 20 (37): 2937-2948 - 2024-10-21 20(37), DOI: 10.1080/14796694.2024.2413841

Autors: Valachis, A; Othman, M; Biganzoli, L; Risi, E; Christopoulou, A; Fjermeros, K; Fountzila, E; Geisler, J; Gomez-Bravo, R; Rodriguez, AB; Munoz-Mateu, M; Karihtala, P; Utriainen, M; Kosmidis, P; Koutras, A; Linardou, H; Spathas, N; Lindman, H; Schiza, A; Martínez-Ballestero, I; Meattini, I; Visani, L; Psyrri, A; Ballesteros, S; Aviles, JMR; Basdekis, I; Mastoraki, K; Hay, SD; Jenset, M; Fotis, T; Nanou, C; Fricker, S; Santaholma, M; Graaf, GD; Kanters, T; Lampropoulos, K; Markou, C; Kosmidis, T

Afiliacions

Resum

Current evidence from both randomized trials and real-world studies suggests that older patients with advanced hormone receptor-positive/HER2-negative (HR+/HER2) breast cancer derive clinical benefit from the addition of CDK4/6 inhibitors to endocrine therapy. However, a higher risk for adverse events due to CDK4/6 inhibitors among older patients is evident, leading to a trend of initiating CDK4/6 inhibitors at lower dose in clinical practice, though without evidence. The aim of the IMPORTANT-trial, a pragmatic, multinational, open-label, partly decentralized randomized trial is to investigate whether lower starting dose of CDK4/6 inhibitors combined with endocrine therapy is comparable to full dose in older (>= 70 years old) patients with advanced HR+/HER2- breast cancer who are assessed as vulnerable or frail based on comprehensive geriatric assessment.

Paraules clau